Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. (5th September 2019)

• Record Type: Journal Article
• Authors: Mngqibisa, Rosie; Kendall, Michelle A; Dooley, Kelly; Wu, Xingye (Shirley); Firnhaber, Cynthia; Mcilleron, Helen; Robinson, Jennifer; Cramer, Yoninah; Rosenkranz, Susan L; Roa, Jhoanna; Coughlin, Kristine; Mawlana, Sajeeda; Badal-Faesen, Sharlaa; Schnabel, David; Omoz-Oarhe, Ayotunde; Samaneka, Wadzanai; Godfrey, Catherine; Cohn, Susan E
• Is Part Of: Clinical infectious diseases. Volume 71:Number 3(2020)
• Page Start: 517
• Page End: 524
• Publication Date: 2019-09-05
• Subjects: HIV -- tuberculosis -- ifampicin -- favirenz -- DMPA; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz863
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Effective contraception is critical to young women with HIV-associated tuberculosis (TB), as unintended pregnancy is associated with increased perinatal morbidity and mortality. The effects of co-administration of efavirenz and rifampicin on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA) are unknown. We hypothesized that clearance of medroxyprogesterone acetate (MPA) would increase when given with rifampicin and efavirenz, thus increasing risk of ovulation. Methods: This pharmacokinetics (PK) study assessed DMPA among HIV/TB coinfected women on an efavirenz-based antiretroviral treatment and rifampicin-based TB treatment. Plasma MPA concentrations and progesterone were measured predose (MPA only) and 2, 4, 6, 8, 10, and 12 weeks after a single DMPA 150 mg intramuscular injection. The primary outcome measure, MPA concentration (<0.1 ng/mL) at week 12, was assessed using exact 95% Clopper-Pearson confidence intervals. MPA PK parameters were calculated using noncompartmental analysis. Results: Among 42 PK-evaluable women from 5 African countries, median age was 32 years and median CD4 was 414 cells/mm 3 . Five women (11.9%; 95% CI, 4.0–25.6%) had MPA <0.1 ng/mL at week 12; of these, one had MPA <0.1 ng/mL at week 10. The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls. There were no adverse events related to DMPA, and progesterone concentrations were <1 ng/mL for all women for the study duration. Conclusions: DMPA, when given with rifampicin and efavirenz, was safe. MPA clearance was higher than in women with HIV not on ART, leading to subtherapeutic concentrations of MPA in 12% of women, suggesting that more frequent dosing might be needed. Clinical Trials Registration: NCT02412436. Abstract : Despite few data on pharmacokinetics interactions between depot medroxyprogesterone acetate (DMPA) and efavirenz/rifampicin, DMPA given with efavirenz/rifampicin was safe but 11.9% of women had medroxyprogesterone acetate concentrations <0.1 ng/mL (concentration associated with increased risk of ovulation). More data are required for definitive dosing recommendations.